BLS Pharmaceuticals Limited (ASX:BLS)

Market Cap	262.17M +141.4%
Revenue (ttm)	47.95M +178.2%
Net Income	8.97M +300.8%
EPS	0.04 +259.7%
Shares Out	229.98M
PE Ratio	28.72
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,289,037
Open	1.140
Previous Close	1.060
Day's Range	1.140 - 1.140
52-Week Range	0.330 - 1.200
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About BLS Pharmaceuticals

BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan. The company offers medical cannabis, MDMA, psilocybin, prescription medicines, probiotics, NADs, and consumer health products under the Dr Watson and PCC brands. It also provides pharmaceutical manufacturing, wholesale, distribution, import, export, and contract drug manufacturing services for investigational and psychotropic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BLS

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error